 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors in Halozyme Therapeutics Inc (HALO) saw new options begin trading this week, for the October 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...

First Week of HALO October 20th Options Trading

Cabot Wealth Management Inc. lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report) by 8.0% during the 2nd quarter, according to the company in its most recent...

Cabot Wealth Management Inc. Reduces Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stephens Investment Management Group LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report) by 1.0% in the 1st quarter, HoldingsChannel.com reports. The institutional...

Stephens Investment Management Group LLC Has $49.91 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report)  Analysts at Zacks Research upped their Q1 2024 earnings per share estimates for shares of Halozyme Therapeutics in a note...

Q1 2024 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Increased by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report)  Analysts at Zacks Research raised their Q1 2024 earnings estimates for Halozyme Therapeutics in a research report issued to...

Zacks Research Weighs in on Halozyme Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HALO)

Halozyme Announces Approval of Roche's Tecentriq Subcutaneous (SC) with ENHANZE in Great Britain Halozyme Announces Approval of Roche's Tecentriq Subcutaneous (SC) with ENHANZE in Great Britain PR...

Halozyme Announces Approval of Roche's Tecentriq Subcutaneous (SC) with ENHANZE in Great Britain

Synovus Financial Corp decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO Free Report) by 28.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 56,054 shares of the biopharmaceutical companys stock after selling 22,821 shares during the quarter...

Synovus Financial Corp Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO  Free Report)  Analysts at Zacks Research decreased their Q4 2023 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research report issued on Tuesday, August 22nd. Zacks Research analyst E. Bagri now forecasts that the ...

Halozyme Therapeutics, Inc. Forecasted to Post Q4 2023 Earnings of $0.67 Per Share (NASDAQ:HALO)

Cerity Partners LLC lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO Free Report) by 15.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,588 shares of the biopharmaceutical ...

Cerity Partners LLC Sells 46,692 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the companys stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $42.41, for a total value of $424,100.00. Following the sale, the senior vice ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $424,100.00 in Stock

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Watchers	4,407
52-Wk Low	$29.85
52-Wk High	$59.46

Market Cap	$5.07B
Volume (M)	847,870.00
52-Wk High	$59.46
52-Wk Low	$29.85

HALO Halozyme Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals